Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (466)	4/30/2003 10:20:46 PM
From: Czechsinthemail	Respond to of 598

mopgcw, Thanks for the GS info. A few items caught my attention. 1. "We have assumed flat revenues from 2002, which may be conservative as we expect new collaborations and expansion of existing collaborations." 2. I hadn't been aware that T487 had shown preclinical activity in transplant rejection. 3. Three of the new IND candidates now have public labels, which perhaps makes them front runners for next to enter clinical trials: T6204, which targets the IL-1/TNF pathway, has shown preclinical efficacy in animal models of ulcerative colitis and collagen-induced arthritis. T659 is an oral agent, which increases HDL cholesterol. T792 is an oral agent that acts through the central nervous system to effect weight loss.